Skip to main content
SpringerLink
Log in

The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease

  • Original Articles
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Thiazolidinediones (TZD) are effective agents for the treatment of hyperglycemia, and appear ideal in diabetic patients with progressive or end-stage renal disease because of its predominant hepatic clearance. Troglitazone, the first available TZD for clinical use, was withdrawn due to safety concerns; however, studies completed with this agent can provide a better understanding of the class effect of TZDs. This study was an open-label, controlled clinical trial examining the safety and efficacy of troglitazone in type 2 diabetic patients with end-stage renal disease (ESRD). Twelve subjects were randomized to parallel study groups and treated for 6 mo with or without troglitazone at a maximum dose of 600 mg/d in addition to continuing their previous diabetes medications (insulin or sulfonylurea). The results showed no significant differences in glycemic control with or without troglitazone treatment for 6 mo. However, there was a significant reduction in insulin dosage with troglitazone treatment (22.9±7.3 units/d) than without troglitazone treatment (54±12.9 units/d) (p<0.05), as well as the change in the insulin dosage from baseline between the two groups (troglitazone, −8.4 units vs control, +4.3 units, p<0.05). Weight changes and aspartate aminotransferase levels greater than 1.5 times the upper limit of normal were not observed in participants of either treatment group. This study demonstrates that troglitazone was safe and effective for the treatment of hyperglycemia in patients requiring dialysis, and strongly supports the clinical use of currently available TZDs in diabetic patients with renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nelson, R. G., Knowler, W. C., Pettitt, D. J., and Bennett, P. H. (1995). In: Diabetes in America. Harris, M. I. (ed.). NIH Publication No. 95-1468, pp. 349–400.

  2. Defronzo, R. (1997). In: Ellenberg and Rifkin’s diabetes mellitus, 5th ed. Porte, D. and Sherwin, R. S. (eds.). Appleton and Lange: Stamford, CT, pp. 993–995.

    Google Scholar 

  3. Charpentier, G., Riveline, J. P., and Varroud-Vial, M. (2000). Diabetes Med. 26(S4), 73–85.

    CAS  Google Scholar 

  4. Viberti, G., Weseman, M. J., Pinto, J. R., and Messent, J. (1996). In: Joslin’s diabetes mellitus, 13th ed. Kahn, C. R. and Weir, G. C. (eds.). Lea and Febiger: Philadelphia, PA, pp. 721–722.

    Google Scholar 

  5. Morioka, T., Emoto, M., Tabata, T., et al. (2001). Diabetes Care 24(5), 909–913.

    Article  PubMed  CAS  Google Scholar 

  6. Mak, R. H. K. (2000). Semin. Dialy. 13(1), 4–8.

    Article  CAS  Google Scholar 

  7. Heinrich, W. L. (ed.). (1994). Principles and practice of dialysis. Williams and Wilkins: Baltimore, MD, pp. 63–75, 89–97, and 111–129.

    Google Scholar 

  8. Saltiel, A. R. and Olefsky, J. M. (1996). Diabetes 45, 1661–1669.

    Article  PubMed  CAS  Google Scholar 

  9. Vamecq, J. and Latruffe, N. (1999). Lancet 354, 141–148.

    Article  PubMed  CAS  Google Scholar 

  10. Schoonjans, K. and Auwerx, J. (2000). Lancet 335, 1008–1010.

    Article  Google Scholar 

  11. Manley, H. J. and Allcock, N. M. (2003). Pharmacotherapy 23(7), 861–865.

    Article  PubMed  CAS  Google Scholar 

  12. Chaplesky, M. C., Thompson-Culkin, K., Miller, A. K., Sack, M., Blum, R., and Freed, M. I. (2003). J. Clin. Pharmacol. 43(3), 252–259.

    Article  Google Scholar 

  13. Thompson-Culkin, K., Zussman, B., Miller, A. K., and Freed, M. I. (2002). J. Int. Med. Res. 30(4), 391–399.

    PubMed  CAS  Google Scholar 

  14. Nelson, S. D. (2001). Adv. Exp. Med. Biol. 500, 33–43.

    Article  PubMed  CAS  Google Scholar 

  15. Williams, M. E. and Roshon, B. (1999). Semin. Dialy. 12(1), 24–31.

    Google Scholar 

  16. Mak, R. H. K. (1994). Diabetes Rev. 2, 19–28.

    Google Scholar 

  17. Stefanovic, V., Nesic, V., and Stojimirovic, B. (2003). Int. J. Artif. Organs 26(2), 100–104.

    PubMed  CAS  Google Scholar 

  18. Chan, N. N., Tong, P. C., So, W. Y., Leung, W. Y., Chiu, C. K., and Chan, J. C. (2004). Med. Sci. Monit. 10(3), PI44–48.

    PubMed  CAS  Google Scholar 

  19. Agrawal, A., Sautter, M. C., and Jones, N. P. (2003). Clin. Ther. 25(11), 2754–2764.

    Article  PubMed  CAS  Google Scholar 

  20. Goldstein, B. J. (2000). Int. J. Clin. Pract. 54(5), 333–337.

    PubMed  CAS  Google Scholar 

  21. Gillies, P. S. and Dunn, C. J. (2000). Drugs 60(2), 333–343.

    Article  PubMed  CAS  Google Scholar 

  22. Freidman, L. M., Furberg, C. D., and DeMets, D. L. (eds.). (1996). Fundamentals of clinical trials, 3rd ed. Mosby: St. Louis, MO, pp. 61–81.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine of the John A. Burns School of Medicine, University of Hawaii-Manoa, USA

    Pharis Mohideen MD, Michael Bornemann, Jared Sugihara, Valerie Sugihara & Richard Arakaki

  2. Diabetes Center at Saint Francis Medical Center, Honolulu, HI

    Viola Genadio

Authors
  1. Pharis Mohideen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Bornemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jared Sugihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Viola Genadio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valerie Sugihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard Arakaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pharis Mohideen MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mohideen, P., Bornemann, M., Sugihara, J. et al. The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease. Endocr 28, 181–186 (2005). https://doi.org/10.1385/ENDO:28:2:181

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/ENDO:28:2:181

Key Words

Search

Navigation